ST Cube FY 2025 Annual ReportBeta
ST Cube annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
ST Cube FY 2025 Annual Report Analysis
Business Overview
- • 92% of FY2025 revenue from cosmetics distribution under own brand Scenearth with exports to Japan and Taiwan
- • Nelmastobart (BTN1A1-targeting immuno-oncology drug) completed global Phase 1 in Sep 2024; entered Phase 2 for NSCLC in Oct 2025
Management Discussion & Analysis
- • Revenue KRW 6.984B (-38.2% YoY from KRW 11.298B); operating loss KRW 23.472B (-3.8% worsening from KRW 22.616B); net loss KRW 21.8B (slightly increased from KRW 21.437B)
- • Cosmetics distribution segment drove gross profit increase, with domestic and overseas Scenearth brand sales growing 57.1% (product) and 42.9% (merchandise); product cost ratio improved from 47% to 37.5%
Risk Factors
- • KRW 2.21B pre-tax profit/loss impact for 10% KRW exchange rate move on foreign currency monetary assets/liabilities
- • KRW 12.0B financial liabilities due within 1 year including KRW 2.5B trade payables and KRW 9.5B lease liabilities
ST Cube FY 2025 Key Financial MetricsDART
Total Assets
KRW 90.2B
▼ -19.4% YoY
Operating Cash Flow
-KRW 19.8B
▲ +17.2% YoY
CapEx
KRW 901.1M
▲ +43.0% YoY
Source: KIFRS consolidated financial data from ST Cube annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding